Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$329.1m

Xeris Biopharma Holdings Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGS:XERS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 May 24BuyUS$10,314John SchmidIndividual5,400US$1.91
14 Mar 24BuyUS$9,720John SchmidIndividual4,500US$2.16
27 Nov 23BuyUS$10,098Jeffrey ShermanIndividual5,400US$1.87
20 Nov 23BuyUS$54,600Steven PieperIndividual28,000US$1.95
20 Nov 23BuyUS$9,954Dawn HalkuffIndividual5,410US$1.84
17 Nov 23BuyUS$50,400John ShannonIndividual30,769US$1.64
16 Nov 23BuyUS$9,815John SchmidIndividual6,500US$1.51
14 Nov 23BuyUS$10,058Marla PerskyIndividual6,370US$1.58
09 Aug 23BuyUS$23,794Paul EdickIndividual10,000US$2.38

Insider Trading Volume

Insider Buying: XERS insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of XERS?
Owner TypeNumber of SharesOwnership Percentage
Private Companies2,1830.00147%
Individual Insiders4,130,0142.79%
Institutions63,878,69343.1%
General Public80,244,77354.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.


Top Shareholders

Top 25 shareholders own 37.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.72%
BlackRock, Inc.
9,960,506US$22.1m-0.51%no data
5.13%
The Vanguard Group, Inc.
7,606,242US$16.9m7.34%no data
3.45%
Caxton Associates LP
5,113,348US$11.4m-9.37%0.68%
2.81%
BioImpact Capital LLC
4,166,496US$9.2m8.3%1.34%
2.17%
State Street Global Advisors, Inc.
3,215,016US$7.1m18%no data
2.05%
Geode Capital Management, LLC
3,045,364US$6.8m5.3%no data
2.04%
Medical Strategy GmbH, Asset Management Arm
3,028,755US$6.7m0%0.34%
1.9%
Rosalind Advisors, Inc.
2,820,170US$6.3m-20.4%4.55%
1.14%
Millennium Management LLC
1,695,753US$3.8m9.55%no data
1.07%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,585,097US$3.5m278%no data
1.04%
Centerbook Partners LP
1,543,873US$3.4m1,300%0.21%
0.85%
Morgan Stanley, Investment Banking and Brokerage Investments
1,256,698US$2.8m4.23%no data
0.78%
Paul Edick
1,161,772US$2.6m-28.4%no data
0.78%
Northern Trust Global Investments
1,159,555US$2.6m-0.5%no data
0.77%
AQR Capital Management, LLC
1,140,275US$2.5m317%no data
0.71%
Redmile Group, LLC
1,046,587US$2.3m0%0.08%
0.68%
Renaissance Technologies LLC
1,009,340US$2.2m-27%no data
0.64%
Columbia Management Investment Advisers, LLC
953,236US$2.1m83.3%no data
0.54%
John Johnson
798,483US$1.8m12.6%no data
0.48%
D. E. Shaw & Co., L.P.
707,011US$1.6m-33%no data
0.42%
Bank of America Corporation, Asset Management Arm
625,087US$1.4m140%no data
0.41%
Invenomic Capital Management LP
604,512US$1.3m6.31%0.18%
0.4%
Knott Partners Management, LLC
600,000US$1.3m54.7%0.4%
0.4%
Stonepine Capital Management LLC
598,086US$1.3m-89.9%0.9%
0.39%
Tudor Investment Corporation
573,186US$1.3m3.57%0.01%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.